Efficacy of Guanabenz Combination Therapy against Chronic Toxoplasmosis across Multiple Mouse Strains
- 20 August 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (9)
- https://doi.org/10.1128/aac.00539-20
Abstract
Toxoplasma gondii, an obligate intracellular parasite that can cause life-threatening acute disease, differentiates into a quiescent cyst stage to establish lifelong chronic infections in animal hosts, including humans. This tissue cyst reservoir, which can reactivate into an acute infection, is currently refractory to clinically available therapeutics. Recently, we and others have discovered drugs capable of significantly reducing brain cyst burden in latently infected mice, but not to undetectable levels. In this study, we examined the use of novel combination therapies possessing multiple mechanisms of action in mouse models of latent toxoplasmosis. Our drug regimens included combinations of pyrimethamine, clindamycin, guanabenz, and endochin-like quinolones (ELQs), and were administered to two different mouse strains in an attempt to eradicate brain tissue cysts. We observed mouse strain-dependent effects with these drug treatments: pyrimethamine + guanabenz showed synergistic efficacy in C57BL/6 mice, yet did not improve upon guanabenz monotherapy in BALB/c mice. Contrary to promising in vitro results demonstrating toxicity to bradyzoites, we observed an antagonistic effect between guanabenz + ELQ-334 in vivo. While we were unable to completely eliminate brain cyst burden, we found that a combination treatment of ELQ-334 + pyrimethamine impressively reduced brain cysts to 95% in C57BL/6 mice, which approaches the limit of detection. These analyses highlight the importance of evaluating anti-infective drugs in multiple mouse strains and will help inform further preclinical cocktail therapy studies designed to treat chronic toxoplasmosis.Keywords
Funding Information
- HHS | National Institutes of Health (AI124723)
- HHS | National Institutes of Health (AI150616)
- HHS | National Institutes of Health (AI060519)
This publication has 27 references indexed in Scilit:
- From Entry to Early Dissemination—Toxoplasma gondii's Initial Encounter With Its HostFrontiers in Cellular and Infection Microbiology, 2019
- Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical PracticeClinical Microbiology Reviews, 2018
- Brains and Brawn: Toxoplasma Infections of the Central Nervous System and Skeletal MuscleTrends in Parasitology, 2017
- Neurons are the Primary Target Cell for the Brain-Tropic Intracellular Parasite Toxoplasma gondiiPLoS Pathogens, 2016
- Toxoplasmosis – A Global Threat. Correlation of Latent Toxoplasmosis with Specific Disease Burden in a Set of 88 CountriesPLOS ONE, 2014
- Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patientsActa Tropica, 2013
- Toxoplasmosis in allo-SCT patients: risk factors and outcomes at a transplantation center with a low incidenceBone Marrow Transplantation, 2010
- Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency SyndromeThe New England Journal of Medicine, 1992
- Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndromeAmerican Journal Of Medicine, 1989
- Assessment of therapy for toxoplasma encephalitis: The TE study groupAmerican Journal Of Medicine, 1987